FDA Experience With Regulation of Naloxone Products to Address the Opioid Crisis and Opportunities for Leveraging Scientific Engagement

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2021-03, Vol.109 (3), p.569-572
Main Authors: Amur, Shashi, Xu, Yun, Hertz, Sharon, Clingman, Chekesha
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.2086